EFA, together with the European Asthma Research and Innovation Partnership (EARIP) partners elaborated a paper setting out what should be the European asthma research priorities.
The European Asthma Research and Innovation Partnership (EARIP) is an EU-funded initiative designed to inform the EU about research and innovation priorities by bringing together key stakeholders across a wide range of disciplines. Partners, EFA among them, have worked over the past three years to develop a coordinated agenda for asthma research and innovation that will position Europe as the global front-runner to address this major health and societal challenge.
The outcome agenda sets out how the EU may capitalise on this via investment in research with high commercial potential that can radically improve the EUs research agenda and public health. EARIP partners should focus on areas with high potential for commercial breakthroughs, such as diagnostics and e-health, and where stakeholders are linked around a common goal. Platforms streamlining communication and closer links between innovators, policy makers and regulators, crucially involving the EU member states, will speed up market uptake.
Asthma, with its high global prevalence and an associated multi-billion global market for treatments, plus its historical underfunding and the demand for new treatments and diagnostics, represents an enormous opportunity to drive substantial economic growth. This paper sets out how the EU may capitalise on this via investment in research with high commercial potential that can radically improve the EUs research agenda and public health.
See the full paper here
For more information about EFA’s role in EARIP please visit the dedicated page.